Open Beta
TREN
MetriLume
TREN

US marketsSER

SEC-sourced researchBeta

SER

Serina Therapeutics, Inc.

Company comparison ↗

Data passport

CIK
0001708599
Exchange
NYSE
Business activity
— · SIC 2834
Financial inputs
6/6
Filing date
Sep 9, 2026
SEC registry record
Operating company
Last updated: SEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table. Exact amounts and source periods: December 2024: 56,000.0000 USD; December 2025: 130,000.0000 USD130K USD0 USD0December 2024December 2025
SER · Exact amounts and source periods · USD
Period endRevenueFiling date
December 202456,000.0000Mar 25, 2026
December 2025130,000.0000Mar 25, 2026

Annual periods · USD

Period endRevenueNet incomeOperating cash flowTotal assetsTotal liabilitiesFiling date
December 2025130,000.0000-19,182,000.0000-17,955,000.00006,951,000.00006,988,000.0000Mar 25, 2026
December 202456,000.0000-11,141,000.0000-17,137,000.00006,724,000.00006,216,000.0000Mar 25, 2026

Financial inputs behind the calculation

Financial inputsUSDPeriod endFiling dateForm
RevenueRevenueFromContractWithCustomerExcludingAssessedTax$130KDecember 2025Mar 25, 202610-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax$56KDecember 2024Mar 25, 202610-K
Net incomeNetIncomeLoss-$19.18MDecember 2025Mar 25, 202610-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities-$17.96MDecember 2025Mar 25, 202610-K
Total assetsAssets$6.95MDecember 2025Mar 25, 202610-K
Total liabilitiesLiabilities$6.99MDecember 2025Mar 25, 202610-K

New filings

Explore methodology ↗